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SL7207 is one of its attenuated strains. SL7207 was ﬁrst made for bacterial vaccine development and its
therapeutic efﬁcacy and safety for hepatocellular carcinoma has not been characterized. In this study, the
inhibitory ability of SL7207-lux on human hepatoma HepG2 cells was tested in vitro and in vivo.
A bacterial luminescent gene cluster (lux CDABE) was transfected into SL7207 to better monitor the
invasion of the bacteria. The results show that SL7207-lux can rapidly enter HepG2 cells and localize in
the cytoplasm. This invasion represses cell proliferation and induces apoptosis. In vivo real-time invasion
studies showed that the bacteria gradually accumulate in the tumor. This enrichment was conﬁrmed by
anatomic observation at 5 days after inoculation. About 40% of tumor growth was inhibited by SL7207-
lux at 34 days post-treatment without signiﬁcant loss of body weight. The area of necrosis of tumor tissue
was clearly increased in the treated group. Bacterial quantiﬁcation showed that the number of colony-
forming units per gram of bacteria within tumor tissue was approximately 1000-fold higher than that of
liver and spleen. These data suggest that attenuated S. typhimurium strain SL7207 has potential for the
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Hepatocellular carcinoma (HCC) is one of the most common
malignancies, accounting for more than 748,300 new cases per
year worldwide. It is the third and second highest cause of
global and Chinese cancer-related deaths, respectively1.
Although chemotherapy, radiotherapy and transplantation
are used in the clinic, the mortality of hepatoma still remains
high because of rapid tumor progression, recurrence, and
drug-resistance. Though other therapeutic options such as
percutaneous ethanol injection, microwave therapy, cryotherapy
and transarterial chemoembolization are available, the thera-
peutic efﬁcacy of these treatments is limited. Development of
novel therapeutic strategies targeting hepatocellular carcinoma is
thus of high priority2.
Using bacteria like Salmonella enterica serovar typhimurium
as alternative cancer therapeutics has sporadically been
explored for some time. Salmonella can invade many different
host cells, but preferentially colonize solid tumors at tumor-to-
liver ratios of 250:1–9000:1, and usually results in tumor
growth retardation3. These bacteria also accumulate in metas-
tases after systemic administration4. Attenuated S. typhimurium
strains were constructed to reduce the toxicity while retaining
the tumor therapeutic effects. The genetically-modiﬁed S.
typhimurium strain VNP20009 has shown promising tumor
therapeutic potential but failed in a phase I clinical trial,
although it could be safely administered to patients5. Another
widely used genetically-modiﬁed S. typhimurium, strain SL7207,
is attenuated by deleting aroA, which is critical for aromatic
amino acid synthesis6. This mutation led to the growth
limitation of SL7207 within the host cells because mammalian
cells do not synthesize aromatic amino acids. SL7207 had been
used as a bacteria vaccine and also showed promising ther-
apeutic potential for breast7, colon8, lung9, prostate cancer10,
neuroblastoma11 and ﬁbrosarcoma12 in pre-clinical experi-
ments. Its usage in hepatic carcinoma is still unknown.
In this study, attenuated S. typhimurium strain SL7207 was
labeled with luciferase to make it easily monitored with a
bioluminescence imaging system. Human hepatoma HepG2
cells were used to test the anti-tumor efﬁcacy of SL7207-lux
both in vitro and in vivo. We propose that SL7207-lux may
safely and effectively inhibit hepatoma tumor growth and
may be a candidate for development as a therapeutic anti-
cancer agent.2. Materials and methods
2.1. Bacterial culture
Attenuated S. typhimurium strain SL7207 (S. typhimurium
2337-65 derivative hisG46, DEL407 [aroA::Tn10 {Tc-s}]), was
a kind gift from Dr. Bruce Stocker.
For strain manipulations and maintenance, bacteria were
grown at 37 1C in Luria–Bertani (LB) medium and on LB
agar plates using standard procedures. In order to determinethe bacterial count, 100 mL of culture was serially diluted
and plated on LB agar. Bacterial colonies were counted
after overnight incubation at 37 1C. The ﬁnal calculation
was based on 1 OD unit of bacteria medium contained 109
bacteria.
2.2. Plasmids and transformation
In order to better monitor colonization of the attenuated S.
typhimurium strain SL7207, we ﬁrst transformed these cells to
express a bacterial luminescent gene cluster (luxCDABE). The
plasmid (pXen-18) containing lux gene operon was bought from
Xenogen (USA). Electroporation was used to transform the lux
gene plasmid operon into the attenuated S. typhimurium strain
SL7207. 100 mL of frozen competent cells were mixed with 1 mL
DNA and treated at 2.5 kV, 25 mF, and 200 O in an electro-
porator (Bio-rad, Gene pulser Xcell System). After electropora-
tion, the bacteria were transferred and cultured in 1 mL of LB
medium for 1 h at 37 1C. Transformed culture (200 mL) was then
plated onto LB plates with 100 mg/mL ampicillin and cultured
overnight at 37 1C.
2.3. Bioluminescence test for monitoring attenuated
S. typhimurium
Attenuated S. typhimurium SL7207-lux cells were cultured in
LB medium at 37 1C with 100 mg/mL ampicillin overnight. For
in vitro detection different amounts of cells were plated in a
blacken 96 well (Costar) and total photon emission from each
sample was captured and quantiﬁed using an IVIS 200
Imaging system (Xenogen Corp.).
2.4. Measurement of bacteria invasion
Human hepatoma HepG2 cells were cultured in MEM medium
supplemented with 100 U/mL penicillin and 100 mg/mL strep-
tomycin with 10% heat-inactivated fetal bovine serum (FBS) at
37 1C in a humidiﬁed atmosphere containing 5% CO2. For
bacterial invasion, HepG2 cells were plated in 24-well plates
and cultured for 24 h. Before treatment the HepG2 cells were
rinsed 3 times with MEM without serum and antibiotic.
Bacteria in log-phase growth were diluted in cell culture
medium MEM without serum and antibiotic and added at
the desired multiplicity of infection (MOI) of 1:25, 1:225, 1:675
and 1:2025. After being exposed to bacterial at 37 1C for 1 h,
cells were washed three times with MEM without serum
and antibiotic and replenished with fresh complete medium
containing 100 mg/mL of gentamicin sulfate for 1.5 h to kill
extracellular but not intracellular bacteria. The cells were
then incubated with complete medium containing 10 mg/mL
of gentamicin sulfate for another 3.5 h. At this time, cells
were washed three times with PBS and intracellular biolumi-
nescence was observed under an IVIS 200 Imaging System
directly13. Adherent bacteria could be released by incubation
with 0.2 mL 0.1% Triton X-100 for 10 min. LB broth (0.8 mL)
was then added and each sample was vigorously mixed.
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count colony-forming units (CFU) on LB agar medium.
Intracellular bacteria also could be shown using immunoﬂuor-
escence staining using an anti-S. Typhimurium 0–4 antibody
[1E6] (abcam).2.5. Cell proliferation assay by SRB
Human hepatoma HepG2 cells were seeded in 24-well plates at
a density of 104 cells/well and then treated with different
amounts of attenuated S. typhimurium SL7207. After 24, 48,
or 96 h, cells were assayed by SRB as previous described14.
The optical density is determined with a micro-culture plate
reader (BioTek Elx800) at 570 nm. The percentage of cell
survival was calculated.2.6. Apoptosis assay
Human hepatoma HepG2 cells were seeded in 24-well plates at
a density of 2 104, then treated with quantiﬁed amounts of
attenuated S. typhimurium SL7207. After 48 h, cells were
stained by the DeadEndTM Fluorometric TUNEL System
Kit (Promega, Madison, Wisconsin, USA) following the
manufacturer’s instruction.
To quantify apoptosis, caspase-3 activity was assayed by
Caspase-Glo assay kit (Promega, Madison, USA) according to
the manufacturer’s protocol. Caspase-3 activity was expressed as
the fold increase as compared to untreated cells. The experiments
were repeated three times with duplicate slides for each condition.Figure 1 Bioluminescence of attenuated S. typhimurium SL7207-
lux. Bacteria were diluted in 100 mL LB medium and seeded into a
blacken 96-well-plates. The plate was imaged using an IVIS 200
imaging system.2.7. In vivo tumor model
Mice used in this study were purchased from the Institute for
Experimental Animals, Chinese Academy of Medical Sciences
& Peking Union Medical College. The study protocols were in
accordance with the regulations of Good Laboratory Practice
for non-clinical laboratory studies of drugs issued by the
National Scientiﬁc and Technologic Committee of People’s
Republic of China.
Female BALB/c nude mice (18–22 g) were implanted by
subcutaneous injection of 5 106 human hepatoma HepG2 cells
on the right ﬂank. After 3 weeks, the tumors were aseptically
dissected and pieces of tumor tissue (2 mm3 in size) were
transplanted s.c. by a trocar into mice. When the tumor size was
over 100 mm3, mice were divided into groups (n¼6) and injected
intravenously with saline or 5 106 attenuated S. typhimurium
SL7207-lux twice a week for 5 weeks. Tumor size was measured
every 3 days and tumor volume was determined by
lengthwidth2/2. Every week after injection the animals were
placed on a warmed stage inside the camera box (IVIS 200
Imaging System, Xenogen) to observe tumor growth. At day 34,
tumors were taken from the mice and weighed. The tumor growth
inhibition (TGI) for SL7207 treatment group was calculated by the
fomula: [1–tumor weight (treated)/tumor weight (control)] 100%.
In addition, tumor tissues were taken from nude mice on day 34
for hematoxylin–eosin staining after formalin–ﬁxation and
parafﬁn-embedding. Bacteria inside the tissue were released and
quantiﬁed as after homogenization of the tissue with a DY89-II
tissue grinder (Xinzhi Biotechnology Comp., Ningbo, China).2.8. Statistics
Data were described as means7SD of the indicated number of
separate experiments. A one-way analysis of variance was
performed for multiple comparisons. If there was signiﬁcant
variation between treatment and control groups, the mean
values were compared using Student’s t-test. P-values less than
0.05 were considered signiﬁcant.3. Results
3.1. Attenuated S. typhimurium SL7207-lux invaded HepG2
cells and located in the cytoplasm
In order to better detect the location and investigate the
invasion process of the attenuated S. typhimurium strain
SL7207, we ﬁrst transformed these cells to express a bacterial
luminescent gene cluster (luxCDABE). Brieﬂ, a plasmid pXen-
18 containing the lux gene operon was transfected into
attenuated S. typhimurium SL7207. The resulting attenuated
SL7207-lux cells could express the bioluminescence genes and
produce light stably at 37 1C without exogenous substrate
supplied. After seeding bacteria in a blacken plate biolumines-
cence was measured with an IVIS 200 Imaging System.
Bioluminescence was positively correlated to the number of
cells. The minimum detectable number of bacteria was
3.75 106 bacteria per well (Fig. 1).
To measure in vitro cell invasion efﬁciency of SL7207-lux,
bacteria in logarithmic growth phase (Fig. 2A) were seeded
onto the plates of hepatoma HepG2 cells and co-cultured for
3.5 h. Intracellular bioluminescence was observed under an
IVIS 200 Imaging System directly. The results showed that
intracellular bioluminescence was positively correlated to the
number of bacteria added to the medium of the HepG2 cells
Figure 2 Attenuated S. typhimurium SL7207-lux invaded HepG2 cells and located in the cytoplasm. SL7207-lux bacteria (A) were seeded
with HepG2 and co-incubated for 3.5 h, after which luminescence was measured (B). The number of intracellular bacteria in treated
HepG2 cells was determined (C). Bacterial intracellular location was determined by immunoﬂuorescent staining with a Salmonella-speciﬁc
antibody (D).
Figure 3 In vitro effects of SL7207-lux on human hepatoma
HepG2 cells. Cells were exposed to SL7207 at different MOI for
24, 48 and 96 h, respectively, and cell survival was measured by
SRB assay.
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number of colony-forming units (CFU) of bacteria was
positively correlated to the intracellular bioluminescence
(Fig. 2C). In addition, immunoﬂuorescent staining showed
that bacteria were localized mainly in the cytoplasm (Fig. 2D).
These results showed that attenuated S. typhimurium SL7207-
lux can rapidly enter HepG2 cells and that invasion correlates
with the size of the inoculation.
3.2. SL7207-lux inhibited the proliferation of human
hepatoma HepG2 cells
To explore the anti-proliferative effect of SL7207-lux on
human hepatoma HepG2 cells, HepG2 cells were exposed to
SL7207-lux at different multiplicities of infection (MOI) for
24, 48 and 96 h, respectively. SRB assay results showed that
SL7207 treatment inhibited cell proliferation in HepG2 cells.
The inhibitory rate of different MOI (1:25, 1:225, 1:675,
1:2025) was from 8 to 40% with 48-h treatment, and the
highest inhibitory rate was increased up to 60% after 96-h
prolonged treatment (Fig. 3).
3.3. SL7207-lux induced HepG2 cell apoptosis
To determine whether S. typhimurium SL7207 induced HepG2 cell
apoptosis, a TUNEL assay was done after 48-h treatment of
SL7207-lux. The results showed a signiﬁcant increase in the
percentage of TUNEL positive cells after SL7207-lux treatment
(Fig. 4A). This result was conﬁrmed by a caspase-3 activity assay,
which showed SL7207 markedly induced activation of caspase-3(Fig. 4B). Taken together, we conclude that SL7207-lux treatment
reduced cell viability of HepG2 cells through apoptosis.
3.4. Optical imaging in living animals
In order to observe in vivo real-time invasion of attenuated
S. typhimurium SL7207 into tumor, an optical imaging system
was used to track SL7207-lux in a hepatoma HepG2 xenograft
model. At different times after SL7207-lux inoculation, biolumi-
nescence of the nude mice could be detected. The results showed
that the bacteria concentrated in the mouse liver area at 20 min,
Figure 5 SL7207-lux proliferation and aggregation in human
hepatoma HepG2 xenografts. After SL7207-lux inoculation for
the indicated times, the bioluminescence of the nude mice was
monitored by optical imaging system to track the bacteria. Five
days after inoculation an anatomic observation was done to check
the number of bacteria in the tumor, lung and liver (bottom).
Figure 4 SL7207-lux induced HepG2 cell apoptosis. Cells were
treated with S. typhimurium strain SL7207-lux (MOI 1:2025) for
the indicated times and the TUNEL assay was measured to
calculate the rate of apoptosis (apoptotic cells/total cells) (A) and
caspase-3 activity assay (B).
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later, the number of bacteria in the tumor site was about 400- to
1000-fold higher than in liver and other areas (Fig. 5). This result
was concordant with the previous studies.
3.5. SL7207-lux inhibited the growth of hepatoma HepG2
xenografts in nude mice
In order to evaluate the potential effect of SL7207-lux on
tumor growth in vivo, hepatoma HepG2 xenograft tumors
(about 100 mm3) were treated intravenously with 5 106
SL7207-lux two times a week for 5 weeks. The results
showed that SL7207-lux signiﬁcantly reduced tumor volume
by 36% TGI (tumor growth inhibition) and tumor weight by
42% TGI (Fig. 6A, C and Table 1). Compared with the
control group, the body weight of treatment group was not
signiﬁcantly reduced after 34 days of treatment (Fig. 6B and
Table 1).
Bacteria in the liver and tumor tissue were released and
quantiﬁed as in vitro, and showed that the number of colony-
forming units (CFU) per gram of bacteria within tumor tissue
was 1000-fold higher than that of liver or spleen (Fig. 6D). As
shown in Fig. 6E, the necrosis area of tumor tissue in the
control group was less than in SL7207-lux-treated group.4. Discussion
Hepatocellular carcinoma yields highly malignant tumors
leaving the patients with an average survival time of less than
one year. Most hepatic carcinoma patients are diagnosed at anadvanced stage with cirrhosis and are not eligible for surgery.
For those patients who cannot undergo surgery and liver
transplantation, development of new therapeutic strategies
which are efﬁcient and speciﬁc but less toxic is of high
priority15.
In recent years different types of bacteria targeting cancer have
been explored and several have been tested in pre-clinical experi-
ments and/or clinical trials. Among those, Salmonella enterica
serovar typhimurium (S. typhimurium) is a promising potential
selection, and some genetically modiﬁed strains have been
produced to yield better therapeutic effects and fewer side effects.
Salmonella strains are highly immunologic and may induce septic
shock mainly caused by the presence of lipid A16. The Salmonella
strain VNP20009, which carries genomic deletions of msbB (gene
product involved in synthesizing lipopolysaccharide) and purl to
reduce septic shock potential while retaining tumor-targeting
in vivo has been widely used in anticancer therapeutic studies.
However, these studies have not been able to demonstrate a
Figure 6 SL7207-lux restrained the growth of human hepatoma HepG2 xenografts. Mice with xenograft hepatoma HepG2 cell tumors
were treated intravenously with SL7207-lux twice a week for 5 weeks. Tumor volume (A) and mouse body weight (B) was measured twice
a week. At day 34, mice were killed and tumors were isolated (C). Liver, spleen and half of each tumor were homogenized to release and
quantify the bacteria as in vitro (D). The remaining half of each tumor was used for HE staining (E). N: necrosis region; V: vital tumor
rim; M: margin.
Table 1 Anti-tumor effects of SL7207-lux on tumor
volume of human hepatoma HepG2 tumor-bearing
nude mice.
Group Mean weight (g) Mean tumor
volume (mm3)
Mouse Tumor
Control 21.4771.54 2.3870.38 2614.997380.23
SL7207-lux 23.2771.93 1.5270.21 1512.417351.15
TGI – 36% 42%
nPo0.05 vs. control; TGI: tumor growth inhibition, n¼6.
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VNP20009, thereby hampering entry of the bacteria into the
tumors. The human immune system reacts more sensitively than
that of the mouse to VNP20009 and rapidly clears it from the
blood. SL7207, another genetically modiﬁed S. typhimurium strain
which is less attenuated than VNP20009, has retained more
tumor-toxic characteristics and may have better therapeuticeffects. In this study, we investigated the antitumor activity of
SL7207-lux both in vitro and in vivo, and found that it effectively
induced cancer cell apoptosis. We also monitored the ability of the
bacteria to invade hepatoma cells in vitro and in vivo.
Bacteria normally would be cleared quickly by the immune
system in immune-competent mice. But necrotic areas of
tumors have a high concentration of nutrients and lack of
immunologic surveillance, providing a wonderful place for
auxotrophic Salmonella growth and survival. Bacterial growth
in tumor necrotic areas damaged surrounding tumor tissue
and inhibited tumor growth. In this study, though immune-
deﬁcient nude mice were used, Salmonella could still be
enriched in tumor sites and inhibit tumor growth, which also
has been shown by at least one other in vivo study8, indicating
that bacteria in the mice had been cleared by mechanisms
other than the immune system and might be worthy of
further study.
Bacterial invasion and survival within cells is a very
complicated process. Some studies have shown that low
concentrations of bacteria are degraded by tumor cells, but
Baowei Li et al.568high concentrations of bacteria permit entry into cells, leading
to cell lysis5,17. In this study, cell proliferation studies showed
that low concentrations of bacteria did not signiﬁcantly affect
cell growth. In vivo studies showed that the animal body
weight also was not affected by bacteria, indicating that
SL7207-lux had low toxicity when the dosage was low. When
the concentration of bacteria was high, cell apoptosis was
induced and resulted in the inhibition of cell proliferation.
Bacteria enriched in the tumor area (about 1000-fold higher
than in liver and spleen tissues) led to about 40% tumor
growth inhibition in vivo, which was consistent with the high
concentrations of bacteria in vitro.
In this study, a bacterial luminescent gene cluster was
transfected into attenuated S. typhimurium SL7207-lux cells
and in vitro and in vivo invasion of bacteria into hepatoma
cells was monitored. SL7207-lux showed signiﬁcant effects on
human hepatoma HepG2 cells in vitro and in vivo without
toxicity, indicating that Salmonella might be developed into a
tool for cancer therapy. With this in mind, SL7207 could be
developed into RNAi-based anticancer vector.
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